Stereotaxis, Inc.
Stereotaxis, Inc. (NASDAQ: STXS) designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. The company's proprietary Robotic Magnetic Navigation technology uses computer-controlled magnetic fields to directly control the tip of flexible interventional… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Stereotaxis, Inc. does
In the company’s own words
Stereotaxis, Inc. (NASDAQ: STXS) designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. The company's proprietary Robotic Magnetic Navigation technology uses computer-controlled magnetic fields to directly control the tip of flexible interventional catheters and devices, enabling physicians to perform complex endovascular procedures with improved precision, stability, reach, and safety compared to manual techniques.
The company operates as a single business segment focused primarily on electrophysiology applications, specifically cardiac ablation procedures for treating arrhythmias, with secondary focus on complex interventional cardiology procedures and emerging applications in neurovascular and peripheral interventions. Stereotaxis' primary products include the Genesis RMN and GenesisX RMN robotic systems, the Odyssey Solution and next-generation Synchrony and SynX digital information platforms, various interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and compatible x-ray systems offered through strategic partnerships.
The company has documented clinical evidence across over 500 publications and real-world experience from more than 150,000 procedures performed at over one hundred hospitals globally. Stereotaxis maintains strategic relationships with leading technology companies including fluoroscopy system manufacturers, catheter providers, and electrophysiology mapping system developers to ensure product compatibility and integration. In July 2024, the company acquired Access Point Technologies EP, Inc., which manufactures the Map-iT diagnostic catheter portfolio and provides in-house catheter development and manufacturing capabilities.
Stereotaxis holds extensive intellectual property protection including 43 issued U.S. patents and 6 issued foreign patents, with key patents extending through 2028 and beyond. The company markets its products globally through a direct sales force, distributors, and sales agents supported by clinical specialists. As of December 31, 2025, the company maintained approximately $9.1 million in system backlog. The company operates manufacturing facilities in St. Louis, Missouri and Rogers, Minnesota, with quality systems certified to ISO 13485 and MDSAP standards.
Company details
- Sector
- Healthcare
- Industry
- Electromedical Apparatus
- Headquarters
- ST.LOUIS, MO
- Fiscal year end
- December
- CIK
- 1289340
- SIC
- 3845
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Stereotaxis, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Stereotaxis, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Stereotaxis, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Stereotaxis, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Stereotaxis, Inc.'s last four quarterly filings that the numbers alone won't show?”